Biopharma · FDA Approvals · Stock
BCRX BioCryst
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal che…
Assets on file: berotralstat, navenibart
Catalyst calendar
Dated catalysts for BCRX, including recently decided ones.
Recent first-hand events
Every first-hand event for BCRX, newest first.
BCRXBioCrystBioCryst grants Neopharmed Gentili European rights to navenibart
BioCryst signed an exclusive European licensing deal for navenibart in HAE. The company receives $70M upfront plus up to $275M in milestones and 18-30% royalties. The Phase 3 program remains on track for a US regulatory filing by end of 2027.
BCRXBioCrystBioCryst: FDA approves ORLADEYO oral pellets for pediatric HAE
FDA approved the NDA for an oral pellet formulation of once-daily ORLADEYO (berotralstat) for prophylactic treatment of hereditary angioedema in children aged 2 to <12 years. This expands the approved indication from adults/adolescents to the first and only oral prophylactic option for this pediatric population.
Peers by market cap
Companies in the same sector closest to BCRX in market value.
PURRHyperliquid StrategiesMarket cap $2.2B
IMNMImmunomeMarket cap $2.1B · 2 tracked drugs · 1 upcoming catalyst
AUPHAuriniaMarket cap $2.2B · 1 tracked drug · 1 upcoming catalyst
XNCRXencorMarket cap $2.2B · 1 tracked drug
PVLAPalvellaMarket cap $2.1B · 1 tracked drug · 1 upcoming catalyst
VERAVera TherapeuticsMarket cap $2.2B · 1 tracked drug · 2 upcoming catalysts
HRMYHarmony BiosciencesMarket cap $2.3B · 4 tracked drugs · 4 upcoming catalysts
ZYMEZymeworksMarket cap $2.1B · 2 tracked drugs · 22 upcoming catalysts